Clinical Conversations by Experts View all

Featured Videos

PCF 2022

Prostate cancer genomic classifier Videos

Latest Videos

Bladder Cancer Videos

Recent Physician-Scientist Review Articles

  State of the Evidence Review Articles

Transformative Evidence

  Curated by Clinicians: Educational Forum with Videos, Abstracts and Conference Information

Bladder Cancer Detection

Reno, Nevada ( -- Photocure ASA, The Bladder Cancer Company, announces the publication of the study “Clinical and Economic Impact of Blue Light Cystoscopy in the Management of NMIBC* at U.S. Ambulatory Surgical Centers: What is the Site-of-Service Disparity?” in Urologic Oncology this week. The research objective was to quantify the clinical and economic impact of the incorporation of BLC in the management of NMIBC in ambulatory surgical centers (ASCs) considering 2022 Center for Medicare Services (CMS) patient-physician coverage and reimbursement.

Clinical Application And Utility Of PYLARIFY

Reno, Nevada ( -- Lantheus Holdings, Inc., a company committed to improving patient outcomes through diagnostics, radiotherapeutics, and artificial intelligence solutions that enable clinicians to Find, Fight and Follow disease, showcased artificial intelligence (AI) data at the 2022 European Association of Nuclear Medicine (EANM) Annual Meeting in Barcelona, Spain.


Context: Randomized controlled trials (RCTs) have shown that addition of docetaxel or androgen receptor axis–targeted therapy (ARAT) to androgen deprivation therapy (ADT) or addition of ARAT to ADT and docetaxel improves overall survival (OS) in metastatic hormone-sensitive prostate cancer (mHSPC). However, it is unknown whether docetaxel, when given as part of triplet therapy, has an independent OS benefit.


Darolutamide is a potent androgen-receptor inhibitor that has been associated with increased overall survival among patients with nonmetastatic, castration-resistant prostate cancer. Whether a combination of darolutamide, androgen-deprivation therapy, and docetaxel would increase survival among patients with metastatic, hormone-sensitive prostate cancer is unknown.


Novartis announced that the US Food and Drug Administration (FDA) has accepted and granted Priority Review to the company’s New Drug Application (NDA) for 177Lu-PSMA-617, an investigational targeted radioligand therapy for the treatment of metastatic castration-resistant prostate cancer (mCRPC) in the post androgen receptor pathway inhibition, post-taxane-based chemotherapy setting.